Source comparison
BPC-157 for Scar Healing: Peptide Comparison Table
BPC-157 VEGF upregulation, collagen I deposition, fibroblast migration via FAK-paxillin pathway Multiple animal RCTs (2018–2024), no human trials 10 µg/kg topical or 200–500 µg subcutaneous −20°C lyophilized, 2–8°C reconstituted, use within 28 days Strongest p
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, collagen I deposition, fibroblast migration via FAK-paxillin pathway
- Multiple animal RCTs (2018–2024), no human trials
- 10 µg/kg topical or 200–500 µg subcutaneous
- −20°C lyophilized, 2–8°C reconstituted, use within 28 days
- Strongest preclinical evidence for accelerated wound closure and improved scar architecture, but human data absent
- TB-500 (Thymosin Beta-4)
- Actin sequestration, promotes cell migration and angiogenesis
- Animal studies, limited human case reports
- 2–5 mg subcutaneous 2x/week
- −20°C lyophilized, 2–8°C reconstituted, use within 30 days
- Effective for soft tissue repair, overlapping mechanism with BPC-157 but less specific to collagen remodeling
- GHK-Cu (Copper Peptide)
- Stimulates collagen synthesis, antioxidant activity, MMP modulation
- In vitro and small animal studies, cosmetic use common
- 1–5 mg/mL topical
- Room temperature stable in solution
- Well-tolerated for cosmetic scar reduction, but slower-acting and less potent than BPC-157 in wound closure velocity